Sugi Predict

Sugi Predict / Targets / CACNA1B

CACNA1B

Voltage-dependent N-type calcium channel subunit alpha-1B · Q00975 · CACNA1B on Sugi Atlas →

109,512 patent compounds predicted against CACNA1B, 62,763 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL65831 SCHEMBL65831 1.00 19/20
SCHEMBL65900 SCHEMBL65900 1.00 19/20
SCHEMBL65926 SCHEMBL65926 1.00 19/20
SCHEMBL66204 SCHEMBL66204 1.00 19/20
SCHEMBL66401 SCHEMBL66401 1.00 19/20
SCHEMBL66736 SCHEMBL66736 1.00 19/20
SCHEMBL66740 SCHEMBL66740 1.00 19/20
SCHEMBL65764 SCHEMBL65764 0.87 19/20
SCHEMBL66235 SCHEMBL66235 0.87 19/20
SCHEMBL65661 SCHEMBL65661 0.85 19/20
SCHEMBL66758 SCHEMBL66758 0.83 19/20
SCHEMBL65747 SCHEMBL65747 0.78 19/20
SCHEMBL65749 SCHEMBL65749 0.77 19/20
SCHEMBL65455 SCHEMBL65455 0.75 19/20
SCHEMBL66139 SCHEMBL66139 0.75 19/20
SCHEMBL66267 SCHEMBL66267 0.74 19/20
SCHEMBL66385 SCHEMBL66385 0.67 19/20
SCHEMBL66386 SCHEMBL66386 0.67 19/20
SCHEMBL66541 SCHEMBL66541 0.67 19/20
SCHEMBL66542 SCHEMBL66542 0.67 19/20

Clinical trials — most relevant to CACNA1B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination PHASE4UNKNOWN
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy PHASE3COMPLETED
Role of Intralipid in Management of Organophosphorus Poisoning PHASE2/PHASE3WITHDRAWN
Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia PHASE2/PHASE3COMPLETED
4-Aminopyridine in Episodic Ataxia Type 2 PHASE2WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients PHASE2WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients PHASE2WITHDRAWN
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain PHASE2COMPLETED
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome PHASE1/PHASE2NOT_YET_RECRUITING
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis PHASE2COMPLETED
Ultra-Early Gamma Knife Stereotactic Radiosurgery for TN PHASE2RECRUITING
Pathophysiology Based Therapy of Early Onset Epileptic Encephalopathies PHASE2WITHDRAWN
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development nanRECRUITING
Verapamil in Supraclavicular Brachial Plexus Block nanUNKNOWN
International CRDS Registry nanRECRUITING
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY) nanCOMPLETED
Evaluation of A Clinical Diagnostic Test for CRDS nanRECRUITING
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services nanUNKNOWN
Factors Affecting Salt Intake in Young Adults nanUNKNOWN
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study nanUNKNOWN
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED
Presternal Magnesium With Bupivacain Versus Bupivacain Only for Postoperative Pain Relief in Open Heart Surgery nanCOMPLETED
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
The Prevalence of RYR1-related Disease nanNOT_YET_RECRUITING
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13) nanNOT_YET_RECRUITING
Postoperative Pain Alleviation in Open Heart Surgery nanCOMPLETED
The Use of Antiarrhythmic Drugs in Pediatrics nanUNKNOWN
The Energetic Origin of Neurodegeneration in MS nanCOMPLETED
A Causal Role for Voltage-gated Cav1.2 Calcium Channels in Mediating 5G FR1 Effects on Sleep-associated Brain Health in Humans nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a CACNA1B binder may also engage these)

ProteinNameSimilarity
Q05152 — 1.000 Q05152 →
P54282 — 1.000 P54282 →
P97445 — 1.000 P97445 →
Q02294 — 1.000 Q02294 →
O55017 — 1.000 O55017 →
CACNA1A Voltage-dependent P/Q-type calcium channel subunit alpha-1A 1.000 landscape →
P56698 — 0.999 P56698 →
P27884 — 0.999 P27884 →
Q61290 — 0.996 Q61290 →
CACNA1H Voltage-dependent T-type calcium channel subunit alpha-1H 0.994 landscape →
Q07652 — 0.994 Q07652 →
Q02343 — 0.993 Q02343 →
P27732 — 0.992 P27732 →
CACNA1I Voltage-dependent T-type calcium channel subunit alpha-1I 0.992 landscape →
CACNA1E Voltage-dependent R-type calcium channel subunit alpha-1E 0.992 landscape →
CACNA1C Voltage-dependent L-type calcium channel subunit alpha-1C 0.992 landscape →
CACNA1G Voltage-dependent T-type calcium channel subunit alpha-1G 0.991 landscape →
P56699 — 0.991 P56699 →
Q62968 — 0.991 Q62968 →
P15381 — 0.991 P15381 →
O73700 — 0.991 O73700 →
Q9JJV9 — 0.990 Q9JJV9 →
Q6QIY3 — 0.990 Q6QIY3 →
P15389 — 0.990 P15389 →
CACNA1D Voltage-dependent L-type calcium channel subunit alpha-1D 0.990 landscape →
Q9TUI4 — 0.989 Q9TUI4 →
C9D7C2 — 0.989 C9D7C2 →
P22002 — 0.989 P22002 →
O35505 — 0.988 O35505 →
Q9EQ60 — 0.988 Q9EQ60 →